Amendment to Schedule 13D Filing for CDT Equity Inc.

This filing is an amendment (Amendment No. 4) to the Schedule 13D initially filed on September 29, 2023, by Corvus Capital Ltd. ("Corvus") and Dr. Andrew Regan ("Dr. Regan") regarding shares of Common Stock of CDT Equity Inc. (formerly Conduit Pharmaceuticals Inc.). The amendment restates Item 2, detailing the reporting persons as Corvus and Dr. Regan, with Dr. Regan serving as CEO of Corvus. Item 3 is amended to reflect a Sale and Purchase Agreement dated December 8, 2025, where CDT Equity Inc. sold its subsidiary, Conduit Pharmaceuticals Limited (CPL), to Corvus. The sale was for a settlement amount of $7,000,000, satisfied through the issuance of 224,800 shares of Common Stock and pre-funded warrants. The exercise of these warrants is subject to stockholder approval and beneficial ownership limitations. Item 4 states Corvus acquired the shares and warrants for investment purposes. Item 5 provides updated beneficial ownership information: Corvus beneficially owns 246,667 shares (12.2% of outstanding shares), and Dr. Regan beneficially owns 386,672 shares (19.1% of outstanding shares), including shares held by Corvus and its subsidiaries. Item 6 incorporates the disclosures from Item 4 regarding the agreement and warrants. Item 7 adds the Sale and Purchase Agreement and Pre-Funded Common Stock Purchase Warrant as exhibits.